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Helicobacter pylori is a Gram-negative, microaerophilic spiral or motile rod that infects about half the 
world’s population with a very high prevalence in the developing world. It is an important aetiological 
factor in the development of gastritis, peptic ulcer disease, gastric atrophy and B cell mucosa 
associated lymphoid tissue (MALT) lymphoma. H. pylori infection is responsible for a significant cause 
of morbidity and mortality imposing a major burden on health care systems world wide. The high 
prevalence of infection in the developing countries has been attributed to poor socioeconomic status 
and sanitation as well as an increased trend of antibiotic resistance. Antimicrobial chemotherapy (two 
antibiotics and a proton pump inhibitor) employed for the treatment of H. pylori infections has emerged 
as the most important means to resolve these infections. However, antimicrobial therapy is fraught with 
a number of inherent limitations such as resistance, cost of treatment, unavailability of drugs in rural 
areas and undesirable side effects necessitating the need to search for alternative approaches from 
natural sources including vegetables, honey and probiotics amongst others. These could form the 
basis of novel low cost, efficient, large-scale and alternative/complementary solutions with minimal side 
effects to decrease or eradicate H. pylori infections in the future. 
 






The spiral-shaped, microaerophilic and Gram-negative 
bacterium, Helicobacter pylori exhibiting four to six uni-
polar sheathed flagella has adapted to thrive in the acid 
environment (Bury-Moné et al., 2003 ) of the stomach of 
humans causing diseases (Módena et al., 2007). H. pylori 
infection is probably one of the most common bacterial 
infections worldwide (Sherif et al., 2004; Tiwari et al., 
2005). It is responsible for a significant cause of morbidity 
and mortality imposing a major burden on the health care 
systems worldwide. The prevalence of H. pylori infection 
varies from 20 - 50% in industrialized countries to over 
80% in developing countries (Feldman, 2001; Ndip et al., 
2004). Childhood appears to be the critical period during 
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crowding and socio-economic deprivation (Feldman, 
2001; Ndip et al., 2004; Dube et al., 2009b). Although, 
the mode of transmission of infection is not completely 
elucidated, most of the available evidence supports 
person-to-person transmission by fecal-to-oral, oral-to-
oral and gastric-to-oral routes (Hardin and Wright, 2002; 
Asrat et al., 2004; Dube et al., 2009a). In children, gastric 
inflammation could cause low gastric secretion which 
results in impaired “gastric barrier” associated with in-
creased susceptibility to enteric infections, a major public 
health concern linked to diarrhoea, malnutrition and 
growth failure in developing countries (Thomas et al., 
2004). 
Acute infection is most commonly asymptomatic and 
maybe associated with epigastric pain, abdominal dis-
tention or bloating, belching, nausea, flatulence and 
halitosis (Meurer and Bower, 2002; Ndip et al., 2008a). 
Prolonged infection and inflammation due to bacterial 





peptic ulcers (gastric ulcers and duodenal ulcers), gastric 
atrophy and B cell mucosa associated lymphoid tissue 
lymphoma (Sherif et al., 2004; Módena et al., 2007). The 
considerable burden of these H. pylori-related sequelae 
means there is an acute demand for accurate diagnosis 
of the infection (Nguyen et al., 2009). Several invasive 
and non- invasive diagnostic tests are available for 
ascertaining the presence of H. pylori infections. Invasive 
tests require endoscopy and include the biopsy urease 
test, histology, fluorescent in situ hybridization, culture 
and polymerase chain reaction (PCR). On the other 
hand, non- invasive tests do not require endoscopy and 
are more convenient. They include 13C-urea breath tests, 
serology and stool antigen enzyme immunoassay tests 
(Gramley et al., 1999; Tanih et al., 2008). Eradication of 
the bacterium is effective in healing peptic ulcers, pre-
venting ulcer relapse and potentially decreases the risk of 
progression to gastric carcinoma (Sherif et al., 2004; 
Tanih et al., 2009a). 
The growing resistance of the organism to conventional 
antimicrobial agents is a source of concern to clinical 
microbiologists all over the world. Currently, treatment of 
symptomatic individuals is with a regimen containing two 
antimicrobial agents along with a proton pump inhibitor 
(Malekzadeh et al., 2004; Bytzer and O’Morain, 2005; 
Tanih et al., 2009b). Drug costs and availability, treat-
ment side effects, non compliance, antibiotic inactivation 
by pH often result in treatment failure (Alarcón et al., 
1999; Wong et al., 2002; Ndip et al., 2008a). As a result, 
efforts are being made to develop new antimicrobial 
agents from natural sources for better chemotherapeutic 
effects (Adebolu, 2005). Therefore, a non antibiotic agent 
which is cheap, readily available, effective and free from 
side effects might be of utmost importance for the eradi-
cation of H. pylori infections (Stamatis et al., 2003; Ndip 
et al., 2007a; Ndip et al., 2008b). 
In this paper, an overview of the current treatment regi-
men for H. pylori infection, factors implicated in treatment 
failure as well as prospective natural remedies which may 
provide future control/treatment strategies for this noto-
rious pathogen were presented. 
 
 
CONVENTIONAL ANTIMICROBIAL THERAPY  
 
H. pylori infection is a serious, chronic, progressive and 
transmissible infection associated with significant morbi-
dity and mortality, which alone emphasizes the priority of 
developing adequate prophylactic or therapeutic mea-
sures (Scarpignato, 2004). Development of a successful 
treatment for H. pylori infection has been fraught with 
difficulty. Its location within the  stomach (that is, the 
mucus lining the surface epithelium, deep within the 
mucus-secreting glands of the antrum, attached to cells 
and even within the cells ) provides a challenge for anti-
microbial therapy (Ricci et al., 2002; Romano and 
Cuomo, 2004). In addition, the gastric mucosa is a hostile  




environment for antimicrobial therapy because drugs 
must penetrate the thick mucus and may need to be 
active at pH values below neutral (Malekzadeh et al., 
2004; Romano and Cuomo, 2004). Moreover, emerging 
bacterial resistance presents an added challenge (Hardin 
and Wright, 2002). 
The purpose of treatment of H. pylori infection in any 
clinical situation is the eradication of the bacterium from 
the fore gut or stomach (Harris and Misiewicz, 2002). 
Eradication is defined as a negative test for the bacterium 
four weeks or longer after treatment (Harris and 
Misiewicz, 2002; Romano and Cuomo, 2004). It results in 
the effective healing of ulcers (Meurer and Bower, 2002), 
prevents ulcer relapse (Leodotler et al., 2001; Ables et 
al., 2007), reduces recurrence of gastric cancer 
(Steinbach et al., 1999; Lee et al., 2008) and potentially 
decreases the risk of progression to gastric carcinoma 
(Bytzer and O’Morain, 2005; Ndip et al., 2008a). For 
successful eradication of the bacterium, it is imperative 
that the clinician be aware of the current antimicrobial 
susceptibility profiles of the isolates within the region 
(Sherif et al., 2004). Consequently, antibiotic recom-
mended for patients may soon differ across regions of the 
world because different areas have begun to show resis-
tance to particular antibiotics (Ndip et al., 2005). Such 
regional variation in resistance patterns probably reflects 
geographical variation in local antibiotic-prescription prac-
tices and antibiotic use and abuse (Ndip et al., 2008a), as 
drug control is much tighter in some areas than others 
(Tanih et al., 2009b). 
 
 
Drugs used for Treatment 
 
H. pylori infections are treated with drugs that kill the 
bacteria (antibiotics), reduce stomach acid (H2 blockers 
and proton pump inhibitor (PPI)) and protect the stomach 





The discovery of H. pylori in 1983 led to renewed interest 
in bismuth compounds, because these were found to 
successfully treat the infection in combination with anti-
biotics (Alarcón et al., 1999; Ford et al., 2008). Bismuth 
compounds (colloidal bismuth sub citrate and bismuth 
subsalicylate) may reduce the development of resistance 
to co-administered antibiotics (Goodwin et al., 1988) and 
are also effective at treating H. pylori strains with esta-
blished resistance to other antibiotics (Midolo et al., 1999; 
Andersen et al., 2000). 
Bismuth compounds actions include a reduction in 
intracellular ATP levels (Sox and Olson, 1989) and inter-
ference with the activity of urease enzyme, a key enzyme 
of H. pylori (Lee, 1991; Romano and Cuomo, 2004). Also, 
they induce the formation of  an  ulcer-specific  coagulum  




(Sandha et al., 1998), preventing acid back diffusion 
(Meurer and Bower, 2002) and inhibit protein and cell 
wall synthesis as well as membrane function (Bland et 
al., 2004; Meurer and Bower, 2002; Romano and Cuomo, 
2004). Furthermore, they cause an increase in the syn-
thesis of prostaglandin E2 (Sandha et al., 1998), detach-
ment of H. pylori from the gastric epithelium and a 
reduction in capsular polysaccharide production (Meurer 
and Bower, 2002; Romano and Cuomo, 2004). There-
fore, the properties of bismuth compounds are bacte-
ricidal for H. pylori (Larsen et al., 2003). The bismuth 
compounds are extremely potent cytotoxic agents when 
attached to a monoclonal antibody as these can target 
leukemia, lymphoma and other tumors. Interestingly, H. 
pylori is incriminated in mucosa associated lymphoid 
tissue lymphoma, thus there is a clear connection bet-
ween anti-tumor activity and bismuth compounds 
(Wotherspoon, 1998). 
Side effects encountered with this drug include 
darkening of oral cavity and stool (Meurer and Bower, 
2002; Ford et al., 2008), nausea and gastrointestinal 
upset (Stenstrôm et al., 2008).  Recently, bismuth con-
taining regimen has been recommended as a potential 
first line therapy, because there have been concerns that 
PPI-based triple therapies for H.pylori do not lead to a 





Two types of acid-suppressing drugs might be used and 
these are H2 blockers and PPI. H2 blockers work by 
blocking histamine, which stimulates acid secretion. They 
include cimetidine, ranitidine, famotidine and nizatidine. 
On the other hand, PPI suppress acid production by 
halting the mechanism that pumps the acid into the sto-
mach. They also include omeprazole, lansoprazole, rabe-
prazole, pantoprazole and esomeprazole (Harris, 1998; 
Gendull et al., 2003). 
H. pylori prefers an acidic environment, so increasing 
the gastric pH with the use of histamine H2 receptor anta-
gonist (H2RA) or PPI has been shown to improve the 
effectiveness of antibiotic therapy (De Boer et al., 1995). 
In the presence of ulcer disease, PPI have largely re-
placed H2RA   because of their ability to provide more 
rapid pain relief and better control of pH (Meurer and 
Bower, 2002; Romano and Cuomo, 2004). PPI’s also 
display several pharmacological actions that give them a 
place in the eradication. These include: 
 
i) They exert an antibacterial action against H. pylori 
(Nakao and Malfertheiner, 1998). 
ii) By increasing intra gastric pH, they allow the 
microorganisms to reach the growth phase and become 
more sensitive to antibiotics such as Amoxicillin and 
Clarithromycin (Farthing et al., 1998; Scott et al., 1998; 





ii) They increase antibiotic stability (Gustarson et al., 
1995) and efficacy (Erah et al., 1997).  
iv) By reducing gastric emptying (Parkman et al., 1998) 
and mucus viscosity (Goddard and Spiller, 1996), they in-
crease the gastric residence time and mucus penetration 
of antimicrobials (Pedrazzoli et al., 2001). 
 
In addition, some of these anti -ulcer drugs show in vitro 
synergy when tested with some antibiotics (Alarcón et al., 
1999). Seemingly, the increased absorption and tissue 
penetration of antimicrobial agents that occur with ele-
vated gastric mucosal levels caused by omeprazole may 





H. pylori is susceptible in vitro to commonly used anti-
biotics such as; amoxicillin (AMOX), tetracycline (TET), 
metronidazole (MET) and clarithromycin (CLR) (Alarcón 
et al., 1999). Of the H. pylori isolates collected in Came-
roon, Ndip et al. (2008a) found 56.1% to be susceptible 
to TET, 55.3% to CLR, 14.4% to AMOX and only 6.8% to 
MET. Currently, these antibiotics were administered in 
combination, with no single agent ever used as mono-
therapy because of lack of efficacy and the potential 
development of resistance (Alarcón et al., 1999; Hardin 
and Wright, 2002). 
Metronidazole (prodrug) is highly active against H. 
pylori and requires activation by bacterial nitroreductases 
(Meurer and Bower, 2002). However, other studies have 
reported high rates of resistance to this drug (Ndip et al., 
2008a; Tanih et al., 2009b). The bacterium possesses a 
number of enzymes with the potential to reduce MET. 
The reduced nitroimidazole cause loss of the helical 
structure of bacterial DNA, break strands and thus, 
impaired bacterial infection (Romano and Cuomo, 2004). 
MET can have unpleasant adverse effects (e.g. nausea, 
a metallic taste, dyspepsia) and a disulfiram-like reaction 
with alcohol consumption (Hardin and Wright, 2002; 
Stenström et al., 2008). 
Clarithromycin is recognized as the key antibiotic for H. 
pylori treatment because of its powerful bactericidal effect 
in vitro compared with other available molecules 
(Megraud, 2004; De Francisco et al., 2007). Co-admini-
stration with PPI significantly increases the concentration 
of CLR in the antral mucosa and the mucus layer (Meurer 
and Bower, 2002). Results of studies showing approxi-
mately 90% H. pylori eradication with triple therapy 
regimens using CLR have led to the widespread use of 
this antibiotics (Romano and Cuomo, 2002), though it is 
more expensive than other antibiotic agents (Hardin and 
Wright, 2002). Adverse effects with CLR include a bitter 
metallic taste (Ables et al., 2007), dysgeusia (Hardin and 
Wright, 2002), gastrointestinal upset and diarrhea 
(Stenström et al., 2008). 





antibiotic for H. pylori infection (Meurer and Bower, 
2002). Its action against H. pylori is pH dependent and 
therefore requires co-administration with a PPI (Meurer 
and Bower, 2002; Hardin and Wright, 2002; Romano and 
Cuomo, 2004). It inhibits the synthesis of bacterial cell 
wall after absorption into the bloodstream and subse-
quent delivery into the gastric lumen (Romano and 
Cuomo, 2004). Side effects include gastrointestinal up-
set, diarrhea and headache (Stenström et al., 2008). 
Tetracycline has demonstrated in vitro efficacy against 
H. pylori and is active at low pH (Romano and Cuomo, 
2002). It is inexpensive and is a close derivative of the 
polycyclic naphthacene carboxamides. Therefore, it 
inhibits protein synthesis and bind specifically to the 30S 
ribosomal subunit. Tetracycline can cause discoloration 
of teeth in children, photosensitivity reaction and gastro-
intestinal upset (Hardin and Wright, 2002). 
Furazolidone, a synthetic nitro furan appears to be 
effective for many H. pylori strains which are resistant to 
MET (Meurer and Bower, 2002). However, it is described 
as an alternative to MET; patients should be warned 
against using alcohol or monoamine oxidase inhibitors 





The treatment of H. pylori infection can be likened to the 
treatment of tuberculosis because it is a multidrug 
regimens and an adequate length of time is needed to 
eradicate the organism (Meurer and Bower, 2004). 
Combination of drug regimens are essential to minimize 
the risk of promoting antimicrobial (namely to MET and or 
CLR) resistance (De Boer and Tytgat, 2000; Scarpignato, 
2004). The only conditions for which such treatment is 
strongly recommended on the basis of unequivocal 
evidence, are peptic ulcer disease and low grade gastric 
MALT lymphoma (Tanih et al., 2009a). Monotherapy in 
which antibiotic agents alone were used in the 
eradication of the bacterium was inefficient, making it 
imperative to use dual, triple or even quadruple therapy 
(Alarcón et al., 1999). 
Dual therapy regimen refers to the combination of PPI’s 
or Ranitidine bismuth citrate (RBC) and one antibiotic 
usually AMOX or CLR (Wu and Sung, 1999). The first 
dual therapy combining omeprazole with AMOX had un-
predictable efficacy ranging from 20 to 90% (Bayerdorffer 
et al., 1995; Laine et al., 1997). The dual therapy is, how-
ever, more reproducible when AMOX is replaced with 
CLR (Wu and Sung, 1999). 
 Triple therapy regimen is the most popular and 
standard treatment regimen for the cure of H. pylori infec-
tion (De Boer and Tytgat, 2000; Hardin and Wright, 
2002). It consists of an acid-suppressant (PPI or RBC) 
and two antimicrobials (Wu and Sung, 1999). The first 
PPI- based triple therapy was described by Bazzoli et al. 
(1993) and  its  good  efficacy  (eradication  rate  of  more  




than 80%) has been supported in several studies in 
Europe (Lind et al., 1999; Malfertheiner et al., 1999) and 
Canada (Zanten et al., 1999). The choice of antibiotics 
decides the efficacy of the PPI-based triple therapy, thus 
CLR being included in the therapy ensures high efficacy 
and reproducible results (Wu and Sung, 1999). 
Because bacterial resistance to MET or CLR results 
primarily from previous treatment failure, first choice 
treatment should never combine CLR and MET in the 
same regimen (Romano and Cuomo, 2004). In fact, even 
though this combination is highly effective, patients who 
are not cured will have at least single, and usually 
double, resistance (Peitz et al., 2002) and no viable 
empirical treatment remains afterwards. 
RBC-triple therapy has proven to be effective in eradi-
cating H. pylori with cure rates ranging from 80 to 96% 
(Laine et al., 1997; Savarino et al., 1997). One week RBC 
based triple therapy is now increasingly considered as an 
effective regimen for H. pylori eradication (Wu and Sung, 
1999). 
Quadruple therapy regimen consists of bismuth, a PPI 
and two antibiotics (Hardin and Wright, 2002; Meurer and 
Bower, 2002; Malekzadeh et al., 2004). Currently, qua-
druple therapy is mainly reserved as a second line regi-
men in cases of treatment failure (Wu and Sung, 1999; 
De Boer and Tytgat, 2000; Romano and Cuomo, 2002). 
 In addition to H. pylori eradication therapy, patient’s 
education about the need for effective eradication therapy 
and the necessity of completing the initial drug regimen is 
critical. Also, they should be counseled to avoid other 
factors that increase their risk of dyspepsia and peptic 
ulcer disease (Meurer and Bower, 2002). Confirmation of 
the eradication of the bacterium from the fore gut is 
necessary after treatment. This could be done using 13C-
UBT which is the first line post-treatment diagnostic test 
(Malfertheiner et al., 2002). The stool antigen test would 
be an alternative, if UBT is not available (Vaira et al., 
2000). These tests should be performed four weeks after 
therapy (Stenström et al., 2008). Confirmation of cure 
reassures the patients and provides confidence that the 
risk of complications is removed provided the eradication 
is successful. In addition, it facilitates the direction of any 
further management on individual basis, be it re-treat-
ment following treatment failure, or a switch to symptom-
matic therapy (Malekzadeh et al., 2004). 
 
 
FACTORS AFFECTING THE EFFECTIVENESS OF 
TREATMENT REGIMENS 
 
Factors implicated in treatment failure include drug costs 
and availability, treatment side effects (Alarcón et 
al.,1999), lack of penetration of antibiotics into the depth 
of gastric mucosa (Wong et al., 2002), antibiotic inacti-
vation by pH , lack of compliance by patients (Bytzer and 
O’Morain, 2005), lack of correlation between in vitro 
susceptibility test and in vivo efficacy and the presence of  




H. pylori strains with primary or secondary resistance to 
the antimicrobial agents used (Bytzer and  O’morain, 
2005), duration of treatment and antibiotics dosage 
(Gendull et al., 2003). Antimicrobial resistance is in-
creasing and regional variations in susceptibility and 
resistance patterns maybe ascribed to differences in local 
antibiotic prescription practices, antibiotic usage in the 
community and mass eradication programmes for H. 
pylori (Destura et al., 2004; Ndip et al., 2008a). 
Until recently, the recommended duration of therapy for 
H. pylori eradication was 10 to 14 days (Ables et al., 
2007). Potential benefits for shorter regimens include 
better compliance, fewer adverse drug effects, and re-
duced cost to the patient (Meurer and Bower, 2002). 
Low gastric pH seems to affect the activity of antibiotics 
since most are active at neutral pH. The minimal bacte-
ricidal concentrations (MBC) and minimal inhibitory 
concentrations (MIC) of most antibiotics against H. pylori 
(except MET and TET), are dependent on the pH of the 
environment (Megraud and Lamouiatte, 2003). At pH 
values lower than 7 or 7.4, the MIC increases. This is 
why PPI’s are used in therapy so as to increase the pH of 
the stomach, to allow better antimicrobial activity 
(Farthing et al., 1998; Alarcón et al., 1999). In patients 
who are acid hyper secretors, the pH remains low. Con-
sequently, antimicrobial activity may be insufficient to 
eradicate the bacteria. As a result, increasing the dosage 
of PPI in the treatment regimen may have beneficial 
effects (Malekzadeh et al., 2004). 
The most important causes of treatment failure are 
poor compliance on the part of the patients and the deve-
lopment of bacterial resistance to antimicrobial agents 
(Wu and Sung, 1999; Huynh et al., 2004; Ndip et al., 
2007a). Patient compliance can only be improved by 
choosing a simple and well tolerated treatment regimen. 
Also, patients should be educated on the significance of 





Resistance of H. pylori to the limited range of antibiotics 
that have efficacy in its treatment can severely affect 
attempts to eradicate the bacteria. The prevalence of 
bacterial resistance in certain geographical areas can 
influence the selection of first line eradication regimen in 
those regions (Malekzadeh et al., 2004). Bacterial resis-
tance to antimicrobials, however, could be either primary 
(that is, present before therapy) or secondary (that is, 
develop as the result of failed therapy (Romano and 
Cuomo, 2004). Primary resistance in H. pylori has been 
reported in MET (6 - 95%), CLR (0 - 17%), and TET (0-
6%) in different countries (Boyanova et al., 2000; Huynh 
et al., 2004). The issue of resistance primarily concerns 
MET and CLR, however, acquired resistances to AMOX 
and TET have also been reported (Kim et al., 2003), 





Romano and Cuomo, 2004). 
Metronidazole-containing regimens have recently been 
shown to have limited effectiveness because of the in-
creasing prevalence of resistance to this drug (Wang et 
al., 2000; Tanih et al., 2009b). Its prevalence varies from 
10 to 90% in different countries (Wu and Sung, 1999). 
For example, a resistance rate of 28.6% for MET was 
reported by Boyanova et al. (2000) in their attempt to 
assess the primary resistance of four antimicrobials 
against clinical isolates of H. pylori circulating in Sofia, 
Bulgaria. Furthermore in Cameroon, Ndip et al. (2008a) 
documented a very high resistance for MET while Tanih 
et al. (2009b) reported a rate of 95.5% in South Africa. 
Seemingly, Mollison et al. (2000) in their study in 
Australia, registered a resistance of 36% of H. pylori 
isolates against MET. Increasing the dosage of MET 
administered generally improves the result of the therapy 
when treating MET-resistant H. pylori strains (Romano 
and Cuomo, 2004; Stenström et al., 2008). The generally 
high prevalence of metronidazole resistance, for exam-
ple, is probably as the result of the frequent, uncontrolled 
use of nitroimidazole derivatives for the treatment of 
protozoan infections and gynecological problems 
(Alarcón et al., 1999; Ndip et al., 2008a). 
Primary clarithromycin resistance is increasing world-
wide and it has been regarded as the main factor re-
ducing the efficacy of eradication therapy (De Francisco 
et al., 2007). However, the prevalence rate of CLR resis-
tance is 12.9% in the U.S and it is as high as 24% in 
some European countries (Huynh et al., 2004). Acquired 
resistance to CLR frequently develops in individuals after 
initial treatment failure (Wu and Sung, 1999). These CLR-
resistant strains of H. pylori can be treated using a 
regimen containing levofloxacin (Hsu et al., 2008). Never-
theless, there is a trend of rising resistance due to wide-
spread use of CLR in the treatment of upper respiratory 
tract infections. 
The increasing prevalence of antimicrobial resistance 
jeopardizes the success of therapeutic regimens aimed at 
the eradication of infection (Deltenre, 1997). Therefore, 
clinicians should choose the appropriate combination of 
drugs based on sensitivity patterns provided by a local 
reference centre (Meurer and Bower, 2002). Ideally, in 
cases of treatment failure, the antibiotic sensitivity pattern 
of the organism should be established before the second 
line therapy is chosen (Destura et al., 2004). 
 
 
PROSPECTIVE NATURAL REMEDIES 
 
The current increasing prevalence of antimicrobial resis-
tance and its negative impact on the eradication treat-
ment regimens has brought forth the quest for novel 
therapeutic approaches. H. pylori infection is determined 
by several factors, including the type of H. pylori strain, 
the extent of inflammation and the density of H. pylori 





that the risk of the development of peptic ulcer disease 
and gastric cancer increases with an increasing level of 
infection (Tokunaga et al., 2000). On the other hand 
infection could be beneficial for example, by protecting 
the host from the reflux esophagitis and its complications 
(Richter, 2001). Therefore permanent or long-term sup-
pression of H. pylori may at least in some patients, be 
desirable alternatives to eradication treatment as well as 
it could decrease the risk of developing H. pylori-related 
diseases (Blaser, 1999). A non-antibiotic agent, which is 
readily available, inexpensive, and effective and free from 
side effects, might be of utmost importance for the 
eradication of H. pylori (Stamatis et al., 2003; Ndip et al., 
2007b). Natural foods can be attractive as an alternative 





Dietary approaches that would keep H. pylori density and 
infection-mediated inflammation on a low level could be 
of considerable interest in developing low-cost, large-
scale alternative solutions to prevent or decrease H. 
pylori colonization. In this respect; probiotics may close 
the therapeutic gap. A probiotic is defined as a living 
microbial species that, on administration, may have a 
positive effect on bowel micro-ecology and improve 
health conditions (Fuller, 1991). Probiotics have been 
proven to be useful in the treatment of several gastro-
intestinal diseases and can be beneficial in H. pylori-
infected subjects for several reasons. At present, the 
most studied probiotics are lactic acid-producing bacteria, 
particularly Lactobacillus and Bifidobacterium species 
(Rolfe, 2000; Gottenland et al., 2006), but others include 
Weissela confusa and Bacillus subtilis (Pinchuk et al., 
2001; Nam et al., 2002). The action of inhibition of H. 
pylori by probiotics could be nonimmuologically and 
immunologically mediated (Lesbros-Pantoflickova et al., 
2007).  
Nonimmunological barriers such as acidity of the 
stomach and the gastric mucosal represent a first line 
defence against pathogenic bacteria. It has been sug-
gested that the intake of probiotics strengthens this 
barrier by producing antimicrobial substances, competing 
with H. pylori for adhesion receptors, stimulating mucin 
production and stabilizing the gut mucosal barrier 
(Lesbros-Pantoflickova et al., 2007). Certain lactobacilli 
synthesize antimicrobial compounds related to the 
bacteriocin family and also end products of lactic acid 
fermentation such as lactic acid, acetic acid and hydro-
gen peroxide (Sgouras et al., 2004). Lactic acid, in addi-
tion to its antimicrobial effect resulting from the lowering 
of pH, could inhibit the urease enzyme of H. pylori 
(Lesbros-Pantoflickova et al., 2007).  
On the other hand, probiotics could modify the immu-
nologic response of the host by interacting with epithelial 
cells and modulating  the  secretion  of  anti  inflammatory  




cytokines, which would result in a reduction of gastric 
activity and inflammation (Gill, 2003). In addition, it has 
been shown to strengthen the mucosal barrier by stimu-
lating local Ig A responses, thus leading to a mucosa-
stabilizing effect (Vitini et al., 2000). However, distinct 
probiotic strains may generate divergent immune res-
ponses, which, in turn, depend on the host’s immune 
status (Haller et al., 2000). The above-mentioned mecha-
nisms have been demonstrated by some studies 
(Lesbros-Pantoflickova et al., 2007) as shown in Table 1. 
Moreover, implementation of these agents in standard 
anti–H. pylori treatment regimen can increase the poten-
tial of the therapy to have an antimicrobial effect 
(Ushiyama et al., 2003; Franceschi et al., 2005). In addi-
tion, it can improve patients’ compliance to therapy, as a 
result of reducing the occurrence of antibiotic-related 
adverse effects such as headache, nausea and gastro-
intestinal upset (Bergonzelli et al., 2005; Gottenland et 
al., 2006). Other aspects that are considered are the 
contribution of probiotics to the healing of the gastric 
mucosa linked to their antioxidant and anti-inflammatory 
properties (Gottenland et al., 2006). 
Allium vegetables, particularly garlic (Allium sativum L.) 
exhibit a broad antibiotic spectrum against both Gram–
positive and Gram negative bacteria. It has been demon-
strated in vitro that H. pylori is susceptible to garlic extract 
at a fairly moderate concentration. Even H. pylori resis-
tant strains are susceptible to garlic (Mahady and 
Pendland, 2000; Sivam, 2001). 
Capsaicin (hot pepper) consumed as a flavoring spice, 
has pharmacological, physiological and antimicrobial 
effects (Molina-Torres, 1999). Jones et al. (1997) showed 
the effect of capsaicin on H. pylori. Similarly, Zeyrek and 
Oguz (2005) demonstrated in vitro anti-H. pylori activity of 
capsaicin at a concentration of 50 µg/ml against metro-
nidazole-resistant and metronidazole-susceptible clinical 
isolates. There is lower ulcer prevalence in people con-
suming higher amount of pepper compared to controls 
(Kang et al., 1995). It may be advisable to consume raw 
pepper, since it is known that cooking can alter some 
chemical features of Capsicum species and by this way, 
their antibacterial effects may decrease (Cichewicz and 
Thorpe, 1996). For people who do not like hot pepper, 
capsules containing capsaicin may be helpful in preven-
tion and treatment of H. pylori. 
Cranberry (Vaccinium macrocarpon) is a natural fruit, 
native to North America. It is cultivated extensively for 
commercial use in certain states, including Wisconsin, 
Massachusetts, New Jersey, Oregon and Washington 
(Ma et al., 1998). It is a good source of vitamin C, 
fructose and bioflavonoids with anti-oxidant properties, 
which may contribute to the bacteriostatic effect of its 
juice. In a study, Burger et al. (2000) demonstrated that a 
high molecular weight constituent of cranberry juice inhi-
bited H. pylori adhesion to immobilized human gastric 
mucosa in vitro. In addition, Zhang et al. (2005) in their 
preliminary study in Linqu County of Shandong  province,  




Table 1. Mechanisms of Inhibition of H. pylori by probiotics in vitro. 
 
Probiotic Mechanism of inhibition Reference 
L. acidophilus 4356, Lactic acid; lowers pH Aiba et al., 1998 
L. casei 393 Lactic acid; lowers pH Aiba et al., 1998 
L. salivarius WB1040 Lactic acid; inhibits urease enzyme             Aiba et al., 1998 
L. casei strain Shirota Heat-labile substance; affects biosynthesis of DNA and proteins Cats et al., 2003 
L. acidophilus LB Heat-stable protein; induces membrane pore formation  Coconnier  et al., 1998 
L. lactis BH5 Bacteriocin; dissipates membrane potential Kim et al., 2003 
L. acidophilus CRL639 autolysins; induces release of proteinaceous compounds Lorca et al., 2001 
W. confusa PL9001 Class II bacteriocin; induces membrane permeability Nam et al., 2002 
L. johnsonii La 1 Heat-stable substance; causes efflux of intracellular ions Michetti et al., 1999 
L. acidophilus Lactic acid; lowers pH Midolo et al., 1995 
L. casei subsp. Rhamnosus Lactic acid; inhibits urease activity Midolo et al., 1995 
L. reuteri TM 105 Glycolipid-binding proteins; prevents adhesion to target sites Mukai et al., 2002 
B. subtilis 3 Anticoumacin A, B, C; inhibit cytochrome P Pinchulk et al., 2001 




China, suggested that dietary consumption of cranberry 
juice may reduce H. pylori infections in adults, which 





Honey-derived remedies constitute a potential source of 
new compounds that may be useful in the management 
of H. pylori infections. Honey has been recognised for 
medicinal properties since antiquity (Namias, 2003). It is 
a natural substance of very high nutritive value and is 
made, when the nectar and sweet deposits from plants 
are gathered, modified and stored in the honeycombs by 
honeybees of the genera Apis and Meliponinae (Namias, 
2003; Al-jabri, 2005). It contains approximately, 35% 
glucose, 40% fructose, 5% sucrose, 20% water (Sato and 
Miyata, 2000), enzymes, amino acids, organic acids, 
polyphenols (flavonoids and phenolic acids) and 
carotenoid-like substances, Maillard reaction products, 
vitamins, ascorbic acids, -tocopherol and minerals 
(Gheldof et al., 2002). The actual composition of honey 
varies depending on many factors such as pollen source, 
environmental conditions and the processing (Gheldof et 
al., 2002). Therefore, not all have the same antibacterial 
components and this could explain the different 
antibacterial activity for each honey type (Baltrušaityt et 
al., 2007).  
The anti-H. pylori activity of honey has been attributed 
to its anti-microbial properties with regards to its high 
osmolarity, acidity and content of hydrogen peroxide and 
non-peroxide components (Weston, 2000). The major 
antibacterial activity has been found to be due to hydro-
gen peroxide (Temaru et al., 2007), produced by the 
oxidation of glucose by the enzyme glucose-oxidase, 
which is activated by successive dilutions of honey 
(Iurlina and Fritz, 2005). The absolute level of hydrogen 
peroxide in any honey is determined by the respective 
levels of glucose oxidase and catalase (Weston, 2000). 
The non-peroxide activity of honey is usually attributed to 
its phytochemicals (flavonoids and phenolic acids), which 
are derived from plant origin (Yao et al., 2004). Flavo-
noids and phenolic acids are natural anti-oxidants and 
can be extractable by organic solvents (Aljadi and Yusoff, 
2003). The amount of these components may be small or 
diluted in the honey but when extracted, they become 
concentrated and therefore exhibit activity. Almost all 
organisms possess antioxidant defence and repair sys-
tems that have evolved to protect them against oxidative 
damage but insufficient to protect them entirely (Oboh, 
2005). However, honey contains these natural anti-
oxidants which exhibit a wide range of biological effects, 
including antibacterial, anti-inflammatory, anti-allergic, 
antithrombotic and vasodilatory actions (Gómez-
Caravaca et al., 2006). They are reported to scavenge for 
free superoxide and other reactive oxygen metabolites 
liberated during respiratory burst in H. pylori induced 
mucosal damage (Phull et al., 1995; Li et al., 2001).  
Honeys from different countries and regions have a 
wide variability in their antimicrobial activity (Basson and 
Grobler, 2008). This is evidenced in the study carried out 
by Ndip et al. (2007b) to evaluate the in vitro activity of 
some selected honeys used by the population to treat 
gastrointestinal complaints symptomatic of H. pylori 
infection. In this study, it was demonstrated that four 
honey varieties from different geographical locations 
exhibited antibacterial activity against H. pylori. The 
strongest inhibitory activity (82.22%) was demonstrated 
by Mountain honey (from Cameroon) at 75% v/v, followed 
by Capillano® and Manuka™ honeys (from New Zea-
land) (75.56%) and Eco-honey (from Kenya) (73.36%) at 
the same concentration. This is as a result of climatic 
variation which affects the distribution of flowers and 
plant species, from which honey bees gather  nectar  and  




Table 2. Regional variation in honey concentrations against H. pylori isolates. 
 
Country Honey concentration (%v/v) Reference 
Cameroon  10 Ndip et al., 2007b 
America   15 Osato et al., 1999 
New Zealand 5 Somal et al., 1994; Namias, 2003 




sweet plant deposits (Osato et al., 1999; Ndip et al., 
2007b). As a result of profound heterogeneity exhibited 
by H. pylori, in combination with the regional variation in 
the antimicrobial components present in honey, there is a 
difference in the concentration of honey that would inhibit 





H. pylori infection is a serious, chronic, progressive and 
transmissible bacterial infection associated with signifi-
cant morbidity and mortality, which alone emphasizes the 
priority of developing adequate prophylactic or thera-
peutic measures (Scarpignato, 2004). The prevalence of 
antimicrobial resistance is high especially in developing 
countries (Ndip et al., 2004). Antimicrobial therapy for the 
treatment of these infections has emerged as the most 
important means to resolve such infections.  There is 
therefore justification to look for alternative or comple-
mentary eradication therapy. These could provide low-
cost, large-scale alternative solutions to prevent or de-
crease H. pylori colonization, although much attention 
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